非酒精性脂肪性肝病血清标志物研究进展*

doi:10.3969/j.issn.1672-5069.2022.02.037

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (2): 297-300.doi: 10.3969/j.issn.1672-5069.2022.02.037

非酒精性脂肪性肝病血清标志物研究进展^*

黄蝶, 田昊宇综述, 李异玲审校

110001 沈阳市中国医科大学附属第一医院消化内科(黄蝶,李异玲);105期临床三系16班(田昊宇)

收稿日期:2021-03-10 出版日期:2022-03-10 发布日期:2022-03-15
通讯作者: 李异玲,E-mail:lyl-72@163.com
作者简介:黄蝶,女,25岁,硕士研究生。主要从事非酒精性脂肪性肝病基础与临床研究
基金资助:
*国家自然科学基金资助项目(编号:81570519)

Serum markers in patients with non-alcoholic fatty liver disease

Huang Die, Tian Haoyu, Li Yiling

Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang 110001, Liaoning Province, China

Received:2021-03-10 Online:2022-03-10 Published:2022-03-15

摘要/Abstract

摘要： 目的非酒精性脂肪性肝病(NAFLD)是目前全球最流行的慢性肝脏疾病,其主要发生机制包括胰岛素抵抗和氧化应激等。不同血清标志物与NAFLD发病机制密切相关,但尚无明确的定论。本文主要就NAFLD发生发展过程中不同血清标志物的作用作一综述。

关键词: 非酒精性脂肪性肝病, 微小RNA, 瘦素, 脂联素, 角蛋白-18

Abstract: Objective Non-alcoholic fatty liver diseases (NAFLD) is the most prevalent chronic liver disease worldwide at present, and the main mechanisms involved in the pathogenesis include insulin resistance, oxidative stress and so on. Different serum markers are closely related to the pathogenesis of NAFLD, but there is no clear conclusion yet. This article reviewed the important role of different serum markers in patients with NAFLD.

Key words: non-alcoholic fatty liver diseases, MicroRNA, Preptin, Leptin, Adiponectin, CK-18

黄蝶, 田昊宇, 李异玲. 非酒精性脂肪性肝病血清标志物研究进展^*[J]. 实用肝脏病杂志, 2022, 25(2): 297-300.

Huang Die, Tian Haoyu, Li Yiling. Serum markers in patients with non-alcoholic fatty liver disease[J]. Journal of Practical Hepatology, 2022, 25(2): 297-300.

参考文献

[1] Kupčová V, Fedelešová M, Bulas J, et al. Overview of the pathogenesis, genetic, and non-invasive clinical, biochemical, and scoring methods in the assessment of NAFLD.Int J Environ Res Pub Health,2019,16(19):3570.
[2] Araújo AR, Rosso N, Bedogni G, et al. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future.Liver Int,2018,38 (Suppl 1):47-51.
[3] Sarin SK, Kumar M, Eslam M, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol,2020,5(2):167-228.
[4] Ullah R, Rauf N, Nabi G, et al. Role of nutrition in the pathogenesis and prevention of non-alcoholic fatty liver disease: Recent Updates.Int J Biol Sci,2019,15(2):265-276.
[5] Correia de Sousa M, Gjorgjieva M, Dolicka D, et al. Deciphering miRNAs' action through miRNA editing.Int J Mol Sci,2019,20(24):6249.
[6] Cheung O, Puri P, Eicken C, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression.Hepatology,2008,48(6):1810-1820.
[7] Dongiovanni P, Meroni M, Longo M,et al. miRNA signature in NAFLD: A turning point for a non-invasive diagnosis. Int J Mol Sci,2018,19(12):3966.
[8] Liu XL, Pan Q, Zhang RN, et al. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.World J Gastroenterol,2016,22(44): 9844-9852.
[9] Torres LF, Cogliati B, Otton R. Green tea prevents NAFLD by modulation of miR-34a and miR-194 expression in a high-fat diet mouse model.Oxid Med Cell Longev,2019,2019:4168380.
[10] Guo XY, Chen JN, Sun F, et al. circRNA_0046367 prevents hepatoxicity of lipid peroxidation: An inhibitory role against hepatic steatosis.Oxid Med Cell Longev,2017,2017:3960197.
[11] Jia N, Lin X, Ma S, et al. Amelioration of hepatic steatosis is associated with modulation of gut microbiota and suppression of hepatic miR-34a in Gynostemma pentaphylla (Thunb.) Makino treated mice.Nutr Metab (Lond),2018,15:86.
[12] Cai C, Lin Y, Yu C. Circulating miRNAs as novel diagnostic biomarkers in nonalcoholic fatty liver disease: A systematic review and Meta-analysis.Can J Gastroenterol Hepatol,2019,2019: 2096161.
[13] Long JK, Dai W, Zheng YW, et al. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.Mol Med,2019,25(1):26.
[14] Naderi M, Pazouki A, Arefian E, et al. Two triacylglycerol pathway genes, CTDNEP1 and LPIN1, are down-regulated by hsa-miR-122-5p in hepatocytes.Arch Iran Med,2017,20(3):165-171.
[15] Sendi H, Mead I, Wan M, et al. miR-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling.PLoS One,2018,13(7):e0200847.
[16] Akuta N, Kawamura Y, Arase Y, et al. Circulating microRNA-122 and fibrosis stage predict mortality of Japanese patients with histopathologically confirmed NAFLD. Hepatol Commun,2020,4(1):66-76.
[17] Lin HY, Wang FS, Yang YL,et al. MicroRNA-29a suppresses CD36 to ameliorate high fat diet-induced steatohepatitis and liver fibrosis in mice.Cells,2019,8(10):1298.
[18] Yang YL, Kuo HC, Wang FS,et al. MicroRNA-29a disrupts DNMT3b to ameliorate diet-induced non-alcoholic steatohepatitis in mice.Int J Mol Sci,2019,20(6):1499.
[19] Liu MX, Gao M, Li CZ, et al. Dicer1/miR-29/HMGCR axis contributes to hepatic free cholesterol accumulation in mouse non-alcoholic steatohepatitis.Acta Pharmacol Sin,2017,38(5): 660-671.
[20] Rodrigues PM, Afonso MB, Simão AL, et al. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice.Cell Death Dis,2017,8(4):e2748.
[21] Wang XM, Wang XY, Huang YM, et al. Role and mechanisms of action of microRNA-21 as regards the regulation of the WNT/β-catenin signaling pathway in the pathogenesis of non-alcoholic fatty liver disease.Int J Mol Med,2019,44(6):2201-2212.
[22] Loyer X, Paradis V, Hénique C, et al. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression.Gut,2016,65(11):1882-1894.

非酒精性脂肪性肝病血清标志物研究进展^*

Serum markers in patients with non-alcoholic fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	周平, 姚登福, 姚敏. NAFLD与肝细胞恶性转化相关研究新进展^*[J]. 实用肝脏病杂志, 2022, 25(2): 157-160.
[2]	侯文靖, 吴广明, 盖慧慧. 三七总皂苷对非酒精性脂肪性肝病小鼠肝组织脂质沉积及NO/iNOS/NF-κB通路的影响^*[J]. 实用肝脏病杂志, 2022, 25(2): 174-178.
[3]	陈凯, 居峰. 多烯磷脂酰胆碱联合扶正化瘀片治疗非酒精性脂肪性肝病患者肝脏超声脂肪变性评分变化^*[J]. 实用肝脏病杂志, 2022, 25(2): 219-222.
[4]	梁烨倍, 杨春光, 王昆凤, 胡秋明, 李妍辉, 罗琴, 陈浩, 郑亚雄, 余俊, 唐小英, 史华祥, 牛涛, 吴伟, 侯旭宏, 贾伟平. 云南省布朗族成人非酒精性脂肪性肝病流行特点研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 223-226.
[5]	李伟, 黄宇, 钟璟, 韦隽. 外周血PNPLA3 rs738409基因多态性与非酒精性脂肪性肝病遗传易感性研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 227-230.
[6]	莫超艳, 杨有强, 钟嫄, 肖友雪. 非酒精性脂肪性肝病合并2型糖尿病患者血清抵抗素和黄醇结合蛋白4水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(2): 231-234.
[7]	王芳, 高晓霞, 汪庆强. 黄连解毒汤联合益生菌制剂对非酒精性脂肪性肝炎患者中医症候积分和肠道菌群平衡的影响^*[J]. 实用肝脏病杂志, 2022, 25(2): 235-238.
[8]	时牛, 宋洁, 崔天庆, 云宇婷, 郭瑞芳, 吴昆. 超声介导载miR-16-5p微泡联合树突状细胞疫苗对小鼠肝癌皮下移植瘤生长的影响^*[J]. 实用肝脏病杂志, 2022, 25(1): 17-21.
[9]	吕春卉, 李大炜, 王小洁, 康晓平, 韩宗晟, 朱允. 二甲双胍联合辛伐他汀治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究[J]. 实用肝脏病杂志, 2022, 25(1): 50-53.
[10]	任洁, 郝巧歆, 黄成河, 陈勋, 卢欣. 非酒精性脂肪性肝病合并T2DM患者肠道菌群结构变化研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 54-57.
[11]	顾雪香, 李祥玉, 单勤星. 柴胡皂苷a通过影响PPARα信号通路对非酒精性脂肪性肝病大鼠肝脂肪变的保护作用^*[J]. 实用肝脏病杂志, 2021, 24(6): 807-810.
[12]	徐祥涛, 乔飞, 车军勇, 陆玮婷. 化浊通淤汤治疗非酒精性脂肪性肝病患者短期疗效研究[J]. 实用肝脏病杂志, 2021, 24(5): 701-704.
[13]	马上吉, 郑扬, 陈旭峰, 向正国, 吴琳. 老年非酒精性脂肪性肝病合并冠心病患者临床特点及危险因素分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 705-708.
[14]	张译之, 张晓慧, 陈煜. 非酒精性脂肪性肝病动物模型研究进展^*[J]. 实用肝脏病杂志, 2021, 24(5): 761-764.
[15]	王嘉妮, 刘湧, 周忻, 任传路, 缪惠锴. 慢性丙型肝炎患者血清microRNA-1273g-3p水平预测肝硬化价值分析^*[J]. 实用肝脏病杂志, 2021, 24(4): 496-499.